PE00472009A1 - Antibody humanized recombinant anti-interleukin 10 - Google Patents

Antibody humanized recombinant anti-interleukin 10

Info

Publication number
PE00472009A1
PE00472009A1 PE2008001585A PE0015852008A PE00472009A1 PE 00472009 A1 PE00472009 A1 PE 00472009A1 PE 2008001585 A PE2008001585 A PE 2008001585A PE 0015852008 A PE0015852008 A PE 0015852008A PE 00472009 A1 PE00472009 A1 PE 00472009A1
Authority
PE
Peru
Prior art keywords
human
sequence
antibody
germline
identifying
Prior art date
Application number
PE2008001585A
Other languages
Spanish (es)
Inventor
Leonard G Presta
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US51899903P priority Critical
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE00472009A1 publication Critical patent/PE00472009A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/54Interleukins [IL]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • G01N33/6857Antibody fragments

Abstract

SE REFIERE A UN METODO PARA IDENTIFICAR UNA SECUENCIA DE LINEA GERMINAL ACEPTORA PARA UN ANTICUERPO HUMANIZADO, QUE COMPRENDE: A) IDENTIFICAR UN ANTICUERPO NO HUMANO; INVOLVES A method for identifying a SEQUENCE FOR Acceptor Germline humanized antibody, comprising: a) identifying a human antibody NO; B) DETERMINAR LA SECUENCIA DE AMINOACIDOS DE LOS DOMINIOS DE LA CADENA PESADA VARIABLE (VH) Y DE LA CADENA LIGERA VARIABLE (VL) DEL ANTICUERPO NO HUMANO; B) determining the amino acid sequence DOMAINS VARIABLE HEAVY CHAIN ​​(VH) and light chain VARIABLE (VL) NO HUMAN ANTIBODY; C) COMPARAR LA SECUENCIA DEL ANTICUERPO NO HUMANO CON UN GRUPO DE SECUENCIAS DE LINEAS GERMINALES HUMANAS QUE COMPRENDE i) ASIGNAR NUMEROS DE RESIDUOS A LAS SECUENCIAS DE DOMINIOS VH Y VL NO HUMANAS; C) COMPARE THE SEQUENCE OF ANTIBODY NO HUMAN WITH A GROUP OF STREAMS GERM LINE HUMANAS comprising i) assigning residue numbers to the sequences of VH and VL domains non-human; ii) DELINEAR LAS REGIONES CDR Y FR EN LA SECUENCIA; ii) delineating the CDR and FR REGIONS IN THE STREAM; iii) ASIGNAR UN RESULTADO NUMERICO PREDETERMINADO EN CADA POSICION DEL RESIDUO PARA LA CUAL LAS SECUENCIAS DE LINEA GERMINAL NO HUMANA Y HUMANA SON IDENTICAS; iii) NUMERIC DEFAULT ASSIGN A RESULT OF EACH POSITION FOR WHICH THE RESIDUAL SEQUENCES Germline HUMAN AND HUMAN ARE NOT IDENTICAL; Y iv) TOTALIZAR TODOS LOS RESULTADOS DE RESIDUOS PARA GENERAR UN RESULTADO TOTAL PARA CADA SECUENCIA DE LINEA GERMINAL HUMANA; And iv) totalizing ALL SCORES FOR WASTE TOTAL INCOME GENERATING A SEQUENCE FOR EVERY HUMAN Germline; YD) IDENTIFICAR LA SECUENCIA DE LINEA GERMINAL HUMANA CON EL RESULTADO DE RESIDUOS TOTAL MAS ALTO COMO LA SECUENCIA DE LINEA GERMINAL ACEPTORA YD) SEQUENCE IDENTIFYING HUMAN GERM LINE WITH THE RESULT OF WASTE AS HIGHEST TOTAL SEQUENCE Acceptor Germline
PE2008001585A 2003-11-10 2004-11-08 Antibody humanized recombinant anti-interleukin 10 PE00472009A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US51899903P true 2003-11-10 2003-11-10

Publications (1)

Publication Number Publication Date
PE00472009A1 true PE00472009A1 (en) 2009-01-26

Family

ID=34590335

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2008001585A PE00472009A1 (en) 2003-11-10 2004-11-08 Antibody humanized recombinant anti-interleukin 10
PE2004001085A PE09252005A1 (en) 2003-11-10 2004-11-08 Antibody humanized recombinant anti-interleukin 10
PE2008001584A PE00462009A1 (en) 2003-11-10 2004-11-08 Antibody humanized recombinant anti-interleukin 10

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2004001085A PE09252005A1 (en) 2003-11-10 2004-11-08 Antibody humanized recombinant anti-interleukin 10
PE2008001584A PE00462009A1 (en) 2003-11-10 2004-11-08 Antibody humanized recombinant anti-interleukin 10

Country Status (26)

Country Link
US (5) US20050101770A1 (en)
EP (4) EP2123678A1 (en)
JP (4) JP4762148B2 (en)
KR (3) KR20120025618A (en)
CN (2) CN100595212C (en)
AR (3) AR046833A1 (en)
AT (1) AT440867T (en)
AU (2) AU2004290044B2 (en)
CA (2) CA2545255C (en)
CY (1) CY1110557T1 (en)
DE (1) DE602004022855D1 (en)
DK (1) DK1694705T3 (en)
ES (1) ES2329907T3 (en)
HK (1) HK1087722A1 (en)
HR (1) HRP20090517T1 (en)
IL (3) IL175523A (en)
NO (1) NO20062672L (en)
NZ (1) NZ546632A (en)
PE (3) PE00472009A1 (en)
PL (1) PL1694705T3 (en)
PT (1) PT1694705E (en)
RS (1) RS51180B (en)
SG (1) SG155205A1 (en)
SI (1) SI1694705T1 (en)
WO (2) WO2005047324A2 (en)
ZA (1) ZA200603681B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2025702A (en) * 2000-12-07 2002-06-18 Univ Texas Methods of treatment involving human mda-7
WO2002057283A1 (en) * 2001-01-19 2002-07-25 Baylor College Of Medecine Methods and compositions in breast cancer diagnosis and therapeutics
AU2003228267A1 (en) * 2002-03-05 2003-09-22 Board Of Regents, The University Of Texas System Methods of enhancing immune induction involving mda-7
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
CA2548220A1 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
PL212656B1 (en) * 2004-02-23 2012-11-30 Synthes Gmbh BONE SCREW and a device for fixing of bones
JP2008531481A (en) * 2005-02-08 2008-08-14 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents,The University Of Texas System Compositions and methods comprising MDA-7 for the treatment of cancer
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
CA2620802A1 (en) 2005-08-31 2007-03-08 Schering Corporation Engineered anti-il-23 antibodies
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
UA98308C2 (en) * 2006-09-05 2012-05-10 Эли Лилли Энд Компани Anti-myostatin antibody
CA2671538A1 (en) 2006-12-14 2008-06-26 Leonard G. Presta Engineered anti-tslp antibody
US8268803B2 (en) 2006-12-22 2012-09-18 Merck Sharp & Dohme Corp. 5, 6-ring annulated indole derivatives and use thereof
WO2008079352A2 (en) * 2006-12-22 2008-07-03 Schering Corporation Antibodies to cd200r
AU2007339386B8 (en) * 2006-12-22 2013-12-05 Merck Sharp & Dohme Corp. 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
MX2009006880A (en) 2006-12-22 2009-07-03 Schering Corp 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections.
AT554791T (en) 2007-02-23 2012-05-15 Schering Corp Generated anti-il-23p19 antibodies
US20100111966A1 (en) 2007-02-23 2010-05-06 Schering Corporation Engineered anti-il-23p19 antibodies
CN101675076B (en) 2007-02-28 2013-09-18 默沙东公司 Engineered anti-il-23r antibodies
RU2010111551A (en) 2007-08-29 2011-10-10 Шеринг Корпорейшн (US) Substituted indoly derivatives and ways of their application
RU2010111550A (en) * 2007-08-29 2011-10-10 Шеринг Корпорейшн (US) 2,3-substituted indolic derivatives for treating viral infections
AU2008295485B2 (en) * 2007-08-29 2013-09-05 Merck Sharp & Dohme Corp. 2,3-substituted azaindole derivatives for treating viral infections
MX2010005355A (en) * 2007-11-16 2010-06-02 Schering Corp 3-aminosulfonyl substituted indole derivatives and methods of use thereof.
US8765757B2 (en) * 2007-11-16 2014-07-01 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
US8901139B2 (en) * 2008-06-13 2014-12-02 Merck Sharp & Dohme Corp. Tricyclic indole derivatives and methods of use thereof
EP2725037A1 (en) * 2008-09-04 2014-04-30 Vet Therapeutics, Inc. Monoclonal antibodies binding canine CD20
EA201190132A1 (en) * 2009-02-23 2013-01-30 Гленмарк Фармасьютикалс С.А. Humanized antibodies, connecting cd19, and their application
AU2010253791A1 (en) 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
CN102574924A (en) 2009-09-03 2012-07-11 先灵公司 Anti-gitr antibodies
AU2010324871A1 (en) 2009-11-25 2012-06-14 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
MX343228B (en) * 2009-11-30 2016-10-26 Biotest Ag Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle).
EP2516430B1 (en) 2009-12-22 2014-11-05 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
WO2011103441A1 (en) 2010-02-18 2011-08-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
SG183526A1 (en) 2010-03-09 2012-09-27 Merck Sharp & Dohme Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
CN103347894B (en) * 2010-06-19 2017-05-10 纪念斯隆-凯特林癌症中心 Anti-GD2 antibodies
JP2013541499A (en) 2010-07-26 2013-11-14 メルク・シャープ・エンド・ドーム・コーポレイション Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
WO2012050848A1 (en) 2010-09-29 2012-04-19 Schering Corporation Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012069433A2 (en) * 2010-11-23 2012-05-31 Glaxo Group Limited Antigen binding proteins
PL2663579T3 (en) 2011-01-14 2017-09-29 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
SG194485A1 (en) 2011-04-13 2013-12-30 Merck Sharp & Dohme 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
CN102250243B (en) * 2011-07-01 2013-08-28 华绍炳 Antibody to interleukins-15
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
US9512405B2 (en) 2011-12-14 2016-12-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Non-enzymatic method for isolating human adipose-derived stromal stem cells
EP2968545B1 (en) 2013-03-15 2019-03-06 Memorial Sloan Kettering Cancer Center High affinity anti-gd2 antibodies
AR097306A1 (en) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulation of tumor immunity
CN105277638A (en) * 2014-07-22 2016-01-27 沈鹤霄 Monoclonal antibody IgG mass spectrometry sequencing method
BR112017003194A2 (en) 2014-08-19 2017-11-28 Merck Sharp & Dohme antibody or antigen-binding fragment thereof, composition, polypeptide, polynucleotide, vector, host cell, vaccine, vessel or injection device, and methods for antagonizing lag3 in a human patient in need thereof for treating cancer in an individual for administering the antigen-binding antibody, fragment, composition, polypeptide, vaccine, vector or polynucleotide to an individual for producing an antibody or antigen-binding fragment thereof or polypeptide; and to detect the presence of a lag3 peptide or fragment thereof in a sample.
BR112017025562A2 (en) * 2015-05-29 2018-08-07 Dynavax Tech Corporation methods for treating cancer in an individual and for treating a human individual diagnosed with cancer
JP2018516252A (en) * 2015-05-29 2018-06-21 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Combination of anti-IL-10 antibody and CpG-C type oligonucleotide for cancer treatment
EP3377531A2 (en) 2015-11-18 2018-09-26 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
US20190010224A1 (en) * 2015-12-22 2019-01-10 Merck Sharp & Dohme Corp. Formulations of engineered anti-il-10 antibodies
WO2019077037A1 (en) 2017-10-18 2019-04-25 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Methods and compounds for improved immune cell therapy

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv Method for the detection and determination of laagmoleculire compounds and of proteins that are capable of binding specifically these compounds, as well as the test pack.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241B1 (en) 1980-08-07 1988-10-18
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195B1 (en) 1986-01-30 1990-11-27 Cetus Corp
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag Bispecific, oligo, mono- and oligovalent antikoerperkonstrukte, their production and use
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co., Inc. Method for producing recombinant immunoglobuline
US6312680B1 (en) 1990-06-29 2001-11-06 Timothy R. Mosmann Methods of treatment using cytokine synthesis inhibitory factor
US6407213B1 (en) * 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
JPH07502019A (en) * 1991-08-06 1995-03-02
DE69233528D1 (en) 1991-11-25 2005-07-14 Enzon Inc Process for the preparation of multivalent antigen-binding proteins
DE69316921T2 (en) * 1992-08-20 1998-06-04 Schering Corp New uses for il-10
DE19529026C2 (en) * 1995-07-28 1997-06-19 Robert Sabat Monoclonal antibody to human interleukin-10
EP1261376A1 (en) * 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
PE05742002A1 (en) * 2000-12-06 2002-07-02 Wyeth Corp Humanized antibodies that recognize beta amyloid peptide
AU2002368077B2 (en) * 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
US7148038B2 (en) * 2001-10-16 2006-12-12 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof
SI1527100T1 (en) * 2002-03-29 2009-12-31 Schering Corp Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same

Also Published As

Publication number Publication date
IL202681A (en) 2011-10-31
EP2292661A2 (en) 2011-03-09
NZ546632A (en) 2009-07-31
PE00462009A1 (en) 2009-01-26
DK1694705T3 (en) 2009-12-07
AU2004290044B2 (en) 2010-11-18
NO20062672L (en) 2006-06-09
WO2005047326A3 (en) 2005-12-22
US8226947B2 (en) 2012-07-24
CA2812856A1 (en) 2005-05-26
EP1694705B1 (en) 2009-08-26
WO2005047326A2 (en) 2005-05-26
SI1694705T1 (en) 2010-01-29
ZA200603681B (en) 2010-01-27
SG155205A1 (en) 2009-09-30
JP2011087590A (en) 2011-05-06
US20070178097A1 (en) 2007-08-02
AR046833A1 (en) 2005-12-28
JP2014014361A (en) 2014-01-30
AR074779A2 (en) 2011-02-09
US20120282253A1 (en) 2012-11-08
US20100203049A1 (en) 2010-08-12
IL202682D0 (en) 2010-06-30
EP1694705A2 (en) 2006-08-30
IL202681D0 (en) 2010-06-30
AT440867T (en) 2009-09-15
CN100595212C (en) 2010-03-24
RS51180B (en) 2010-10-31
AU2011200606B2 (en) 2012-05-10
EP2123678A1 (en) 2009-11-25
JP4762148B2 (en) 2011-08-31
IL175523A (en) 2011-01-31
KR20120025618A (en) 2012-03-15
HK1087722A1 (en) 2009-11-06
WO2005047324A2 (en) 2005-05-26
CN1906213A (en) 2007-01-31
JP2011062211A (en) 2011-03-31
US20050101770A1 (en) 2005-05-12
HRP20090517T1 (en) 2009-10-31
PT1694705E (en) 2009-11-30
CN102010471A (en) 2011-04-13
KR20060120093A (en) 2006-11-24
CA2545255A1 (en) 2006-05-05
PE09252005A1 (en) 2005-11-29
US8624013B2 (en) 2014-01-07
US7662379B2 (en) 2010-02-16
DE602004022855D1 (en) 2009-10-08
AU2004290044A1 (en) 2005-05-26
PL1694705T3 (en) 2010-02-26
EP2128175A1 (en) 2009-12-02
KR20120023858A (en) 2012-03-13
CY1110557T1 (en) 2015-04-29
ES2329907T3 (en) 2009-12-02
AR074780A2 (en) 2011-02-09
AU2011200606A1 (en) 2011-03-03
IL175523D0 (en) 2006-09-05
JP2008500020A (en) 2008-01-10
US20140112919A1 (en) 2014-04-24
EP2292661A3 (en) 2011-06-22
CA2545255C (en) 2013-06-25

Similar Documents

Publication Publication Date Title
Schroeder Jr Similarity and divergence in the development and expression of the mouse and human antibody repertoires
Mühlenweg et al. The evolution of the school-entry age effect in a school tracking system
Catania Freedom and knowledge: An experimental analysis of preference in pigeons 1
Golding et al. Patterns of somatic mutations in immunoglobulin variable genes
Zinke et al. Potentials and limits of plasticity induced by working memory training in old-old age
WO2004076620A3 (en) Human antibodies specific for interleukin 15 (il-15)
WO2004069331B1 (en) Neural stimulation
NO20150064L (en) antagonistic antibodies
UY28215A1 (en) Quinazolines useful as modulators of ion channels
TW200801040A (en) Binding proteins specific for insulin-like growth factors and uses thereof
MXPA03011365A (en) Human monoclonal antibodies to epidermal growth factor receptor (egfr).
ECSP088530A (en) Aß 1-42 SPECIFIC MONOCLONAL ANTIBODIES WITH THERAPEUTIC PROPERTIES
CL2013003373A1 (en) Protein antigen binding lymphocyte maturation b (bcm); pharmaceutical composition comprising the protein; Use for preparing a multiple myeloma useful for treating or (mm) chronic lymphocytic leukemia (CLL) drug.
ES2100947T3 (en) Methods for producing hybrid protein-coupled receptors.
CY1116458T1 (en) Human antibodies anti-CD38 and Uses thereof
AR069775A1 (en) Bivalent bispecific antibodies
UY28716A1 (en) MAdCAM antibodies
RU2014118773A (en) Antibodies to related cancer-embryonal antigene cell adhesion molecule (ceasam)
CY1111845T1 (en) Molecules COMMITTED me cd20
MY154009A (en) Anti-alpha v beta 6 antibodies
CA2492671A1 (en) Humanized antibody and process for preparing same
PE10342012A1 (en) Anti-factor d Humanized
CY1109106T1 (en) Early diagnosis DISORDER CONFIGURATION OF PROTEIN
NZ568403A (en) CD20-specific antibodies and methods of employing same
PE13612012A1 (en) PCSK9 antagonists

Legal Events

Date Code Title Description
FC Refusal